Home > Gastroenterology > ECCO 2019 > Observational Studies > Infliximab retreatment in luminal Crohn’s disease

Infliximab retreatment in luminal Crohn’s disease

ECCO 2019

After discontinuation of infliximab due to loss of response or intolerance, infliximab retreatment is safe and efficient in more than one third of Crohn’s disease (CD) patients regardless of the reason of prior discontinuation. This was concluded from a prospective, multicentre, observational cohort study, which included 96 patients with active luminal CD who resumed infliximab therapy after at least 6 months of discontinuation [1].

At baseline, patients had clinically (Crohn's Disease Activity Index [CDAI]>150) and objectively active CD. The reintroduction schedule included 3 infliximab infusions at weeks 0, 4, and 8, after a systematic premedication. Maintenance treatment was administered every 8 weeks. At week 26, 34 patients (35%) reached the primary endpoint of efficacy, defined as a CDAI <150 in the absence of infliximab discontinuation or use of corticosteroid therapy, surgery, or another biologic. No significant difference was observed in rat...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on